Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 76
Summary
- Conditions
- Fallopian Tube Cancer
- Ovarian Cancer Recurrent
- Primary Peritoneal Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: randomized clinical trialMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Only males
Description
This exploratory trial is to compare the efficacy of secondary cytoreductive surgery followed by chemotherapy and Niraparib maintenance, versus chemotherapy alone followed by Niraparib maintenance in patients with platinum-sensitive secondary recurrent ovarian cancer who never received secondary cyt...
This exploratory trial is to compare the efficacy of secondary cytoreductive surgery followed by chemotherapy and Niraparib maintenance, versus chemotherapy alone followed by Niraparib maintenance in patients with platinum-sensitive secondary recurrent ovarian cancer who never received secondary cytoreduction when recurrent.
Tracking Information
- NCT #
- NCT03983226
- Collaborators
- Fudan University
- Shanghai Jiao Tong University School of Medicine
- Zhejiang Cancer Hospital
- Sun Yat-sen University
- Investigators
- Principal Investigator: Tingyan Shi, M.D., Ph.D. Shanghai Gynecologic Oncology Group Study Chair: Rongyu Zang, M.D., Ph.D. Shanghai Gynecologic Oncology Group
Get Well Soon